Search Result

Results for "

diabetes mellitus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (1) Acyltransferase (2) Adrenergic Receptor (1) Akt (3) Aldose Reductase (4) AMPK (2) Amylases (2) Amylin Receptor (2) Amyloid-β (1) Antibiotic (1) Apoptosis (8) Autophagy (5) Bacterial (1) CD3 (1) COX (1) Dipeptidyl Peptidase (17) Endogenous Metabolite (5) Estrogen Receptor/ERR (2) FABP (2) FBPase (1) Ferroptosis (2) FGFR (1) Free Fatty Acid Receptor (9) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (1) GCGR (7) GLP Receptor (7) Glucocorticoid Receptor (1) Glucokinase (1) Glucosidase (17) Glutaminase (1) GPR109A (1) GPR119 (1) GSK-3 (2) HIF/HIF Prolyl-Hydroxylase (2) HMG-CoA Reductase (HMGCR) (1) HSV (1) Insulin Receptor (3) Isotope-Labeled Compounds (4) Ketohexokinase (1) Lipoxygenase (1) MAGL (1) Mineralocorticoid Receptor (4) Mitochondrial Metabolism (1) mTOR (1) Na+/K+ ATPase (1) NO Synthase (1) Phosphatase (2) Phospholipase (1) PI3K (2) Potassium Channel (6) PPAR (7) Reactive Oxygen Species (2) RET (1) Ribosomal S6 Kinase (RSK) (1) SGLT (8) Sirtuin (1) Somatostatin Receptor (3) Transthyretin (TTR) (1) TRP Channel (3)
By Research Areas:	Cancer (17) Cardiovascular Disease (13) Endocrinology (9) Infection (4) Inflammation/Immunology (14) Metabolic Disease (128) Neurological Disease (12)

By Targets:

11β-HSD (1)

5-HT Receptor (1)

Acyltransferase (2)

Adrenergic Receptor (1)

Akt (3)

Aldose Reductase (4)

AMPK (2)

Amylases (2)

Amylin Receptor (2)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (8)

Autophagy (5)

Bacterial (1)

CD3 (1)

COX (1)

Dipeptidyl Peptidase (17)

Endogenous Metabolite (5)

Estrogen Receptor/ERR (2)

FABP (2)

FBPase (1)

Ferroptosis (2)

FGFR (1)

Free Fatty Acid Receptor (9)

G protein-coupled Bile Acid Receptor 1 (1)

GABA Receptor (1)

GCGR (7)

GLP Receptor (7)

Glucocorticoid Receptor (1)

Glucokinase (1)

Glucosidase (17)

Glutaminase (1)

GPR109A (1)

GPR119 (1)

GSK-3 (2)

HIF/HIF Prolyl-Hydroxylase (2)

HMG-CoA Reductase (HMGCR) (1)

HSV (1)

Insulin Receptor (3)

Isotope-Labeled Compounds (4)

Ketohexokinase (1)

Lipoxygenase (1)

MAGL (1)

Mineralocorticoid Receptor (4)

Mitochondrial Metabolism (1)

mTOR (1)

Na+/K+ ATPase (1)

NO Synthase (1)

Phosphatase (2)

Phospholipase (1)

PI3K (2)

Potassium Channel (6)

PPAR (7)

Reactive Oxygen Species (2)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

SGLT (8)

Sirtuin (1)

Somatostatin Receptor (3)

Transthyretin (TTR) (1)

TRP Channel (3)

By Research Areas:

Cancer (17)

Cardiovascular Disease (13)

Endocrinology (9)

Infection (4)

Inflammation/Immunology (14)

Metabolic Disease (128)

Neurological Disease (12)

152

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Repaglinide-d5 AG-EE 623ZW d₅	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

Insulin glargine	Insulin Receptor	Metabolic Disease
Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus .

Dutogliptin PHX-1149 free base	Dipeptidyl Peptidase	Metabolic Disease
Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.

Dutogliptin tartrate PHX-1149	Dipeptidyl Peptidase	Metabolic Disease
Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.

Lobeglitazone	Others	Metabolic Disease
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

Adomeglivant 4 Publications Verification LY2409021	GCGR	Metabolic Disease
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

Lobeglitazone sulfate	Others	Metabolic Disease
Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate can be used to prevent type 2 diabetes mellitus (T2DM) .

D-Glucosamine 6-phosphate Glucosamine-6-phosphate	Endogenous Metabolite	Metabolic Disease
D-Glucosamine 6-phosphate is an endogenous metabolite that can be synthesized by glutamine fructose-6-phosphate amidotransferase (GFAT). D-Glucosamine 6-phosphate can be used for the research of diabetes mellitus .

α-Glucosidase-IN-26	Glucosidase	Metabolic Disease
α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC₅₀=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .

Insulin lispro	Others	Metabolic Disease
Insulin lispro is a recombinant human insulin analogue and is one of three rapid-acting insulin analogues available. Insulin lispro can be used for the research of hyperglycaemia in diabetes mellitus .

α-Glucosidase-IN-38	Glucosidase	Metabolic Disease
α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC₅₀ *of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes* mellitus (DM) .**

GPBAR-A	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
GPBAR-A is a specific agonist of the bile acid receptor GPBAR1. GPBAR-A can be used for the research of diabetes mellitus .

Tolbutamide sodium	Apoptosis	Metabolic Disease
Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca ²⁺ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus .

NVP-DPP728 dihydrochloride	Dipeptidyl Peptidase	Metabolic Disease
NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a K_i of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus .

Pal-Glu(OSu)-OH	GLP Receptor	Others
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research .

GLP-1 receptor agonist 7	GCGR	Metabolic Disease
GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b) .

GPR120 Agonist 4	Free Fatty Acid Receptor	Metabolic Disease
GPR120 Agonist 4 (example 1) is a GPR120 agonist，with the EC₅₀ values of 1 μM and 0.35 μM for β-arrestin A and Calcium A. GPR120 Agonist 4 can be used for the research of type II diabetes mellitus .

Lotiglipron PF-07081532	GCGR	Metabolic Disease
Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .

GSK1292263 3 Publications Verification	GPR119	Metabolic Disease Inflammation/Immunology
GSK-1292263 is an orally available GPR119 agonist with pEC₅₀s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .

WWL123	MAGL	Inflammation/Immunology
WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .

BT44	RET	Neurological Disease
BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus .

α-Glucosidase-IN-5	Glutaminase	Metabolic Disease
α-Glucosidase-IN-5 (compound 8) is a potent α-glucosidase inhibitor with an IC₅₀ of 57.9 µM. α-Glucosidase-IN-5 has the potential for the research of diabetes mellitus .

FFA1 agonist-1	Free Fatty Acid Receptor	Metabolic Disease
FFA1 agonist-1 (Compound 17a) is an orally active fatty acid receptor 1 (FFA1) agonist with an EC₅₀ of 0.75 μM. FFA1 agonist-1 can be used for type 2 diabetes mellitus research .

AS2034178 free base	Free Fatty Acid Receptor	Metabolic Disease
AS2034178 free base, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. AS2034178 free base has potential for type 2 diabetes mellitus research .

TC-G 24	GSK-3	Neurological Disease Metabolic Disease
TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases .

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .

D-(+)-Sorbose	Insulin Receptor	Metabolic Disease
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus .

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

N-5984 KRP-204	Adrenergic Receptor	Inflammation/Immunology Cancer
N-5984 (KRP-204) is a potent and selective agonist of β3-adrenergic receptor. N-5984 has the potential for developing as one of the clinically effective drugs for obesity and diabetes mellitus .

Cinnamyl-3,4-dihydroxy-α-cyanocinnamate CDC	Lipoxygenase	Metabolic Disease
Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus .

SSTR5 antagonist 2	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

SSTR5 antagonist 2 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

Picamilon Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid	GABA Receptor	Neurological Disease
Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

Glymidine Glidiazine	Others	Metabolic Disease
Glymidine (Glidiazine) is a hypoglycaemic agent. Glymidine is a lipid soluble sulphapyrimidine derivative. Glymidine appears to stimulate insulin release from pancreas. Glymidine is a possible alternative to the sulphonylureas and biguanides for the research of diabetes mellitus .

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

Vin-F03	Apoptosis	Cardiovascular Disease
Vin-F03 is a potent pancreatic β-cells protective agent with an EC₅₀ of 0.27 µM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research .

Vin-C01	Apoptosis	Cardiovascular Disease
Vin-C01 is a potent pancreatic β-cells protective agent with an EC₅₀ of 0.22 µM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research .

AMG131 INT131	PPAR	Metabolic Disease
AMG131 (INT131), a potent and highly selective PPARγ partial agonist, binds to PPARγ and displaces Rosiglitazone with a K_i of ~10 nM. AMG131 can be used for research of type-2 diabetes mellitus (T2DM) .

FBPase-IN-2	FBPase	Metabolic Disease
FBPase-IN-2 (HS36) is a potent Fructose-1,6-bisphosphatase (FBPase) covalent inhibitor with an IC₅₀ of 0.15 μM. FBPase-IN-2 reduces glucose production in hepatocytes. FBPase-IN-2 can be used for type 2 diabetes mellitus research .

α-Glucosidase α-D-Glucosidase	Glucosidase	Metabolic Disease
α-Glucosidase (α-D-Glucosidase), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM) .

Glipizide CP 28720; K 4024	Potassium Channel	Metabolic Disease
Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (K_ATP) channels among β cells of pancreatic islets of Langerhans .

Kazinol B	NO Synthase Akt AMPK	Metabolic Disease
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .

α-Glucosidase-IN-22	Glucosidase	Metabolic Disease
α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC₅₀ of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .

FABP4/5-IN-4	FABP	Metabolic Disease
FABP4/5-IN-4 (compound E1) is a potent inhibitor of FABP4 and FABP5, with the IC₅₀s of 3.78 μM and 5.72 μM, respectively. FABP4/5-IN-4 plays an important role in metabolism disorder like diabetes mellitus .

FABP4/5-IN-5	FABP	Metabolic Disease
FABP4/5-IN-5 (compound D9) is a potent inhibitor of FABP4 and FABP5,? with the IC₅₀s of 4.68 μM and 10.72 μM, respectively.FABP4/5-IN-5 plays an important role in metabolism disorder like diabetes mellitus .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

740 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-P2802

α-Glucosidase α-D-Glucosidase	Biochemical Assay Reagents
α-Glucosidase (α-D-Glucosidase), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM) .

HY-W587977

3-Hydroxypalmitoylcarnitine 3-Hydroxyhexadecanoylcarnitine	Biochemical Assay Reagents
3-Hydroxypalmitoylcarnitine (3-Hydroxyhexadecanoylcarnitine) is an acylcarnitine. Elevated levels of 3-Hydroxypalmitoylcarnitine are associated with cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) .

Cat. No.	Product Name	Target	Research Area

HY-108719

Insulin glargine

Insulin Receptor Metabolic Disease

Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus .

HY-P0014

Liraglutide 10+ Cited Publications	GCGR GLP Receptor	Metabolic Disease
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P0119A

Lixisenatide acetate 1 Publications Verification	GCGR	Metabolic Disease
Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

HY-P3953

Wy 41747

Peptides Metabolic Disease

Wy 41747 is a long-acting Somatostatin analogue. Wy 41747 can be used for the research of diabetes mellitus .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵N (TFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease
Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes .

HY-P0014S1

Liraglutide-13C5,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₅, ¹⁵N (tetraTFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P2525

GAD65 (206-220)	Peptides	Inflammation/Immunology
GAD65 (206-220) is glutamic acid decarboxylase (GAD) 65-derived peptide, corresponding to residues 180-188. GAD65 is presented to T cells in association with I-Ag7 MHC class II molecules and a major pancreatic antigens targeted by self-reactive T cells in type I diabetes mellitus .

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-108795A

Albiglutide fragment TFA GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .

Cat. No.	Product Name	Target	Research Area

HY-P99614

Fazpilodemab BFKB8488A	FGFR	Metabolic Disease
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .

HY-P99211

Otelixizumab

ChAglyCD3; TRX 4
CD3 Metabolic Disease

Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .

Cat. No.	Product Name	Chemical Structure

HY-15209S

Repaglinide-d5

Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].

HY-B1114S

Gliquidone-d6

Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵N (TFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-P0014S1

Liraglutide-13C5,15N TFA
Liraglutide- ¹³C₅, ¹⁵N (tetraTFA)is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks